167 related articles for article (PubMed ID: 10770782)
1. In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.
Zeckel ML; Preston DA; Allen BS
Antimicrob Agents Chemother; 2000 May; 44(5):1370-4. PubMed ID: 10770782
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Cockerill FR; Steckelberg JM
Diagn Microbiol Infect Dis; 1998 Feb; 30(2):89-92. PubMed ID: 9554174
[TBL] [Abstract][Full Text] [Related]
3. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
[TBL] [Abstract][Full Text] [Related]
4. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Fraise AP; Andrews J; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.
Jones RN; Barrett MS; Erwin ME
Antimicrob Agents Chemother; 1997 Feb; 41(2):488-93. PubMed ID: 9021216
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
Arhin FF; Draghi DC; Pillar CM; Parr TR; Moeck G; Sahm DF
Antimicrob Agents Chemother; 2009 Nov; 53(11):4762-71. PubMed ID: 19738026
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
Harland S; Tebbs SE; Elliott TS
J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.
García-Garrote F; Cercenado E; Alcalá L; Bouza E
Antimicrob Agents Chemother; 1998 Sep; 42(9):2452-5. PubMed ID: 9736584
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci.
Al-Nawas B; Swantes J; Shah PM
Infection; 2000; 28(4):214-8. PubMed ID: 10961526
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
Schwalbe RS; McIntosh AC; Qaiyumi S; Johnson JA; Johnson RJ; Furness KM; Holloway WJ; Steele-Moore L
Antimicrob Agents Chemother; 1996 Oct; 40(10):2416-9. PubMed ID: 8891155
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN
Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
[TBL] [Abstract][Full Text] [Related]
12. Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
Duncan LR; Sader HS; Smart JI; Flamm RK; Mendes RE
J Glob Antimicrob Resist; 2017 Sep; 10():271-276. PubMed ID: 28735051
[TBL] [Abstract][Full Text] [Related]
13. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
Antimicrob Agents Chemother; 2008 Jul; 52(7):2383-8. PubMed ID: 18443115
[TBL] [Abstract][Full Text] [Related]
14. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
[TBL] [Abstract][Full Text] [Related]
15. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
Jones RN; Low DE; Pfaller MA
Diagn Microbiol Infect Dis; 1999 Feb; 33(2):101-12. PubMed ID: 10091033
[TBL] [Abstract][Full Text] [Related]
16. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Zweifel MJ; Wilkie SC; Rodriguez MJ; Thompson RC; Cooper RD
Antimicrob Agents Chemother; 1996 Sep; 40(9):2194-9. PubMed ID: 8878606
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin.
Grüneberg RN; Hryniewicz W
Int J Antimicrob Agents; 1998 Nov; 10(4):271-7. PubMed ID: 9916900
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci.
Noviello S; Ianniello F; Esposito S
J Antimicrob Chemother; 2001 Aug; 48(2):283-6. PubMed ID: 11481302
[TBL] [Abstract][Full Text] [Related]
19. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
Mercier RC; Stumpo C; Rybak MJ
J Antimicrob Chemother; 2002 Jul; 50(1):19-24. PubMed ID: 12096002
[TBL] [Abstract][Full Text] [Related]
20. The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.
Kirk M; Hill RL; Casewell MW; Beighton D
Adv Exp Med Biol; 1997; 418():483-5. PubMed ID: 9331699
[No Abstract] [Full Text] [Related]
[Next] [New Search]
